Genetic Engineering & Biotechnology News lists nine of the most important developments in the biotech industry for 2012. Among the stories for the year was the FDA's issuance in February of a draft guidance for the development and approval of biosimilar drugs. The threat of cuts as part of the "fiscal cliff" loomed over the budgets of the NIH, FDA, CDC and National Science Foundation. The year ended without a blockbuster merger or acquisition but with more new drug approvals from the FDA than 2011.

Related Summaries